Analysguiden publishes research report setting price target of SEK 30 with an optimistic fair value of SEK 60
Hørsholm, Denmark, June 13, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Analysguiden has updated their research reports on ExpreS2ion in June, following the publication of Q1 2022 results, the positive Phase II COVID-19 results for the ABNCoV2 vaccine with respect to omicron protection, and progression of the preclinical-stage breast cancer vaccine candidate ES2B-C001. Analysguiden sets a price target of SEK 30, based on a revised forecast of market size and likelihood of approval, while estimating an optimistic scenario